Needham & Company
-
Needham & Company Maintains a 'Hold' on Warner Chilcott (WCRX); Valuation Paradox
-
Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Chalk One Up in the PIV Win Column As Doryx Goes Generic
-
Needham & Company Maintains a 'Hold' on Warner Chilcott (WCRX); Chilly Ices 2012 Expectations But Shares Hang Tough For Now
-
Needham & Company Maintains a 'Hold' on Warner Chilcott (WCRX); 3Q11 Results Fall Mostly In-Line with Consensus
-
Needham & Company Maintains a 'Hold' on Warner Chilcott (WCRX); Warning Letter Could Complicate “Sweetest” Doryx 150mg Settlement Outcomes
-
Needham & Company Maintains a 'Strong Buy' on Mylan (MYL); Likely Shared Exclusivity Slot Could Result in Upside Scenarios Following IPXL News
-
Needham & Company Maintains a 'Hold' on Warner Chilcott (WCRX); Struggling Rx Trends and New Launches Could Constrain Upside
-
Needham & Company Maintains a 'Hold' on Warner Chilcott (WCRX); No Surprise Given Signaling from Recent 2011 Guidance, 4Q10 Reports Solid Performance
-
Needham & Company Maintains a 'Hold' on Warner Chilcott (WCRX); Initial 2011 Guidance Largely In Line With Prior Signaling; New Product Launch Dynamics Remain Key Upside Determinant
-
Notable Analyst Rating Changes 11/02: MOT, UFS, GNW, EL, JWN, WY, RCL, CS Upgraded; RIMM, PALM, CMCSA, ERJ, GERN Downgraded
-
Needham Upgrades Warner Chilcott (WCRX) to Hold

